Reproduction   citetrack
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS  

Journal of Reproduction and Fertility (1997) 109 103-107
DOI: 10.1530/jrf.0.1090103
Copyright © 1997 Society for Reproduction and Fertility
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Negishi, H.
Right arrow Articles by Koide, S. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Negishi, H.
Right arrow Articles by Koide, S. S.

Prevention and termination of pregnancy in rats by cabergoline, a dopamine agonist

H. Negishi and S. S. Koide

The objective of the study was to clarify the potency and action of cabergoline, a dopamine agonist, in preventing and terminating pregnancy in rats. Cabergoline administered s.c. to female rats on days 1, 2 and 3 of pregnancy prevented implantation of the fertilized ova and development of the embryos. The drug was 100% effective at doses of 10 µg kg–1 day–1 or higher. Serum progesterone determined on day 8 of pregnancy was significantly reduced in rats treated with cabergoline at doses of 5 µg kg–1 day–1 and higher, whereas serum concentrations of oestradiol remained unchanged. Cabergoline at doses of 10 and 20 µg kg–1 day–1 administered s.c. on days 7, 8 and 9 of pregnancy was partially effective (43 and 50%, respectively) in terminating pregnancy, whereas at doses of 30 µg kg–1 day–1 and higher, pregnancy was terminated in all treated rats. Serum concentrations of progesterone on days 12 and 16 of pregnancy were significantly lower in rats treated with doses of 10 µg kg–1 day–1 or higher. Serum prolactin determined on day 4 of pregnancy in rats treated with cabergoline at the effective dose of 10 µg kg–1 day–1 on days 1, 2 and 3 of pregnancy was significantly reduced to 1.7 ± 0.62 ng ml–1 from a pretreatment value of 16.0 ng ml–1. The lowest effective dose of cabergoline in reducing serum prolactin determined on day 8 of pregnancy was 20 µg kg–1 day–1. The present results support the hypothesis that cabergoline acts by inhibiting prolactin production or release, thereby inhibiting progesterone biosynthesis by the ovary.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS  
Copyright © 1997 by the Society for Reproduction and Fertility.